ABAndemirkan Yu. Borukaev

Andemirkan Yu. Borukaev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andemirkan Yu. Borukaev has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The molecular genetic landscape of prostate cancer and its association with thrombosis

    by Попов Анатолий Юрьевич, Anatoly Yu. Popov, Монаков Дмитрий Михайлович, Dmitry M. Monakov, Байтман Татьяна Павловна, Tatiana P. Baitman, Симонов Антон Дмитриевич, Anton D. Simonov, Борукаев Андемиркан Юриевич, Andemirkan Yu. Borukaev, et al.

    Prostate cancer (PCa) remains one of the leading causes of cancer morbidity and mortality in men. In recent years, significant progress has been made in understanding the molecular genetic heterogeneity of PCa, which determines the aggressiveness of the disease, prognosis, and response to therapy. In parallel, evidence is accumulating that the oncological process and its treatment, especially androgen deprivation therapy, are accompanied by an increased risk of venous thromboembolism (VTE). This review examines the association between the PCa molecular landscape and thrombotic complications. We analyzed publications in PubMed, Scopus, Web of Science, and ResearchGate, mainly for 2010–2025. The general mechanisms of the cancer–thrombosis link were considered, including expression of tissue factor, cancer procoagulant, pro-inflammatory cytokines, platelet activation, neutrophil extracellular traps, and suppression of fibrinolysis. The key molecular genetic subtypes of PCa are described in detail: defects in homologous recombination repair genes (BRCA1/2, ATM, CHEK2, PALB2), TMPRSS2-ERG fusion, PTEN deletion, TP53 mutations, and androgen receptor amplification. Aggressive tumor subtypes have been shown to be indirectly associated with a higher risk of VTE through rapid progression, metastasis, intensive treatment, and deterioration of the patient’s general condition. The contribution of androgen deprivation therapy to hypercoagulation is discussed. Interdisciplinary clinical guidelines and an algorithm of actions for geneticists, oncologists, chemotherapists, vascular surgeons, and anesthesiologists and critical care physicians are presented. Particular attention is paid to practical aspects: VTE risk stratification, choice of anticoagulant prophylaxis, and perioperative management. The role of molecular profiling in identifying patients at high thrombotic risk is emphasized. Unresolved problems are identified: the lack of direct biomarkers of tumor thrombogenicity, the need for integrated VTE risk scales taking into account genomic data, and issues of personalization of thromboprophylaxis. It is concluded that a personalized multidisciplinary approach combining PCa molecular profiling, thrombotic risk assessment, and timely VTE prevention is needed.

  • Open Access

    The role of arterial hypertension and antihypertensive therapy in planning nerve-sparing prostatectomy: impact on erectile function

    by A. Yu. Borukaev, T. P. Baitman, L. T. Savin, M. A. Yurlova, N. Yu. Ardashova, D. M. Monakov, А. Ю. Борукаев, Т. П. Байтман, Л. Т. Савин, М. А. Юрлова, et al.

    Assessment of erectile function in patients with prostate cancer is essential when planning nerve-sparing radical prostatectomy. However, reliance solely on validated questionnaires may result in biased estimates because of the subjective nature of self-assessment and the psychological impact of a cancer diagnosis. Therefore, comparing questionnairebased findings with objective methods of erectile function assessment and evaluating factors that may influence erectile function, including arterial hypertension and antihypertensive therapy, is clinically important. Purpose of the study . To evaluate preoperative erectile function in patients with low- and intermediate-risk prostate cancer scheduled for robot-assisted nerve-sparing radical prostatectomy and to assess the impact of hypertension, hypertension grade, and antihypertensive therapy on erectile function. Patients and methods . This prospective study included 150 patients with prostate cancer. Erectile function was assessed using the International Index of Erectile Function‑5 (IIEF‑5), the Erection Hardness Score (EHS), the Sexual Encounter Profile (SEP), and nocturnal penile tumescence (NPT) monitoring with the Androscan MIT device. Statistical analysis was performed using StatTech version 4.13.0. Results . The presence of hypertension was significantly associated with a greater severity of erectile dysfunction (ED), as assessed both by IIEF‑5 (p = 0.030) and NPT data (p = 0.023). The stage of hypertension and the grade of arterial hypertension were associated with deterioration of objective NPT parameters (p = 0.047 and p = 0.031, respectively). Among antihypertensive medications, the use of ACE inhibitors/angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics (predominantly indapamide) was associated with a significant reduction in NPT duration; statins, classified separately as lipid-lowering rather than antihypertensive therapy, showed no significant association. ED severity categories assigned by IIEF‑5 and by Androscan did not match in 62.2 % of cases. Conclusion . Arterial hypertension is an independent preoperative risk factor for erectile dysfunction in patients with prostate cancer. Objective NPT monitoring identifies a substantially higher prevalence of erectile function impairment compared with self-assessment using the IIEF‑5. These findings may be useful in selecting candidates for nerve-sparing prostatectomy.

  • Open Access

    Side effects of androgen deprivation in prostate cancer and their correction: Systematic review

    by L. T. Savin, K. D. Balashova, T. P. Baitman, A. Y. Borukaev, Z. R. Akhmadeev, A. A. Savina, D. M. Monakov, E. Yu. Gritskevich, A. A. Izmailov, A. A. Gritskevich, et al.

    Introduction. Current treatment options for locally advanced and metastatic рrostate cancer offer high survival rates, making quality of life and management of comorbidities, which are often the primary cause of mortality in this cohort, a priority. Metabolic disturbances are one of the most common adverse effects of androgen deprivation therapy. Various treatment options have been described, but no single strategy has been proposed. Aim. To update and systematize modern data on the pathogenesis of metabolic disorders induced by androgen deprivation therapy, and to analyze multidisciplinary approaches to their correction. Materials and methods. A search, analysis, and systematization of relevant publications were conducted in the PubMed, Google Scholar, elibrary.ru, and cyberleninka.ru databases using the following keywords: “prostate cancer” “androgen deprivation therapy”, “metabolic disorders”, “sarcopenia”, “osteoporosis”, and “insulin resistance”. Conference abstracts, dissertation abstracts, and editorial comments were excluded. As a result, 79 of the 158 publications were selected and included in this review. 19 sources were used for the introduction, 60 sources for the main body, and 7 sources, previously mentioned in the main body, for the discussion. Results. Based on this review, we propose recommendations for additional screening of prostate cancer patients receiving androgen-deprivation therapy and present promising approaches to reducing metabolic disturbances and increasing cancer-specific survival. Thus, glucagon-like peptide-1 receptor agonists and statins can not only correct metabolic disorders but also influence carcinogenesis. RANKL inhibitors also have a dual effect, breaking the vicious cycle of bone resorption in metastases. The positive impact of physical activity and nutritional modification on the quality of life and life expectancy of this patient cohort has been demonstrated. Modifications to androgen deprivation therapy through the use of an intermittent regimen or the use of releasing hormone antagonists can also reduce the risk of metabolic complications. Conclusions. An integrated approach to monitoring and treatment improves the quality of life and life expectancy of prostate cancer patients receiving androgen deprivation therapy, as well as the outcomes of systemic antitumor therapy.